Metastatic Melanoma: Scientific Rationale for Sorafenib Treatment and Clinical Results

Publisher： Karger

E-ISSN： 2296-5262|31|7|398-403

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.31, Iss.7, 2008-06, pp. : 398-403

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

BRAF in early stage melanoma: rationale for testing and treatment?

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 1, 2015-07 ,pp. : 9-10

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-12 ,pp. : 123-126

Karger

Access to resources Recommend Favorite

A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 2016-2024

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification

By  

Case Reports in Oncology, Vol. 8, Iss. 1, 2015-02 ,pp. : 83-87

Karger

Access to resources Recommend Favorite

Clinical activity of ipilimumab for metastatic uveal melanoma

By  

CANCER, Vol. 119, Iss. 20, 2013-10 ,pp. : 3687-3695

John Wiley & Sons Inc

Access to resources Recommend Favorite